Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

BIRC3 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

BIRC3 mutation	Small Lymphocytic Lymphoma	BIRC3 mutation	Small Lymphocytic Lymphoma	ibrutinib Sensitive: B - Late Trials ibrutinib Sensitive : B	ibrutinib Sensitive: B - Late Trials ibrutinib Sensitive : B
BIRC3 mutation	Chronic Lymphocytic Leukemia	BIRC3 mutation	Chronic Lymphocytic Leukemia	ibrutinib Sensitive: B - Late Trials ibrutinib Sensitive : B	ibrutinib Sensitive: B - Late Trials ibrutinib Sensitive : B
BIRC3 mutation	Chronic Lymphocytic Leukemia	BIRC3 mutation	Chronic Lymphocytic Leukemia	obinutuzumab Resistant: B - Late Trials obinutuzumab Resistant : B	obinutuzumab Resistant: B - Late Trials obinutuzumab Resistant : B
BIRC3 mutation	Chronic Lymphocytic Leukemia	BIRC3 mutation	Chronic Lymphocytic Leukemia	rituximab Resistant: C3 – Early Trials rituximab Resistant : C3	rituximab Resistant: C3 – Early Trials rituximab Resistant : C3
BIRC3 mutation	Mantle Cell Lymphoma	BIRC3 mutation	Mantle Cell Lymphoma	temsirolimus Resistant: C3 – Early Trials temsirolimus Resistant : C3	temsirolimus Resistant: C3 – Early Trials temsirolimus Resistant : C3
BIRC3 mutation	Chronic Lymphocytic Leukemia	BIRC3 mutation	Chronic Lymphocytic Leukemia	Resistant: C3 – Early Trials Resistant : C3	Resistant: C3 – Early Trials Resistant : C3
BIRC3 mutation	Chronic Lymphocytic Leukemia	BIRC3 mutation	Chronic Lymphocytic Leukemia	Resistant: C3 – Early Trials Resistant : C3	Resistant: C3 – Early Trials Resistant : C3
BIRC3 mutation	Chronic Lymphocytic Leukemia	BIRC3 mutation	Chronic Lymphocytic Leukemia	DC-1-192 Sensitive: D – Preclinical DC-1-192 Sensitive : D	DC-1-192 Sensitive: D – Preclinical DC-1-192 Sensitive : D